News

Women who adhere closely to a Mediterranean diet in their 30s and 40s have a lower risk of Parkinson’s disease later in life, particularly once they reach their mid-60s, a large population-based Swedish study found. The study, “Mediterranean Dietary Pattern at Middle Age and Risk of Parkinson’s Disease: A…

The U.S. National Institutes of Health (NIH) has given a Small Business Innovation Research (SBIR) grant totaling $2.4 million to Cutaneous NeuroDiagnostics (CND) to advance development of its Syn-One Test for diagnosing Parkinson’s and other neurodegenerative diseases. The SBIR grant (R44NS117214), which…

People who are infected with SARS-CoV2 — the virus that causes COVID-19 — may be at greater risk of later developing Parkinson’s disease, researchers suggest in a commentary. In their commentary, “Is COVID-19 a perfect storm for Parkinson’s disease?” published in  Trends in Neurosciences,…

A new method, originally developed to diagnose mad cow disease, shows effectiveness in measuring the buildup of alpha-synuclein in the skin of Parkinson’s disease patients, a new study reports. According to study authors, the findings indicate that using easily collectable patient skin samples may be a feasible method…

The Healthy Longevity Global Grand Challenge, founded by the U.S. National Academy of Medicine, has awarded a grant to develop Entopsis’ non-invasive, urine- and skin swab-based OpsisDx test for the diagnosis of Parkinson’s disease. The research to bring OpsisDx as a diagnostic test for Parkinson’s will…

Ondansetron, an anti-nausea medication usually prescribed to those undergoing cancer therapies, will be tested in an upcoming Phase 2 clinical trial as a possible treatment for visual hallucinations associated with Parkinson’s disease. The study (NCT04167813) — officially the Trial of Ondansetron as a Parkinson’s Hallucination Treatment,…

Higher levels of unacylated-ghrelin, the most prevalent form of ghrelin (acyl-ghrelin) — a gut hormone with neuroprotective properties — suppress nerve cell growth in the hippocampus to affect spatial memory, according to a study in mice. Importantly, the study team also found unacylated-ghrelin levels to be higher-than-normal in people…

Pharmather filed an application with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation be given to ketamine for treating the involuntary jerky movements — known as dyskinesia — that are associated with levodopa use in people with Parkinson’s disease. This condition, known as…

The U.S. Food and Drug Administration (FDA) has named  Cala Trio a breakthrough device as a potential wrist-worn treatment of action tremors in the hands of adults with Parkinson’s disease. This designation is given to medical devices with the potential to more effectively treat diseases that are life-threatening or irreversibly debilitating. It…

Sanofi will provide $1 million in research funding over the next two years to support PD GENEration, a national initiative seeking to increase the availability of genetic testing and counseling for people with Parkinson’s disease living in the U.S. “Genetic testing is critical for advancing…